Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Equity Average: 2011-2025

Historic Equity Average for Aytu Biopharma (AYTU) over the last 12 years, with Sep 2025 value amounting to $21.1 million.

  • Aytu Biopharma's Equity Average fell 26.77% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 26.77%. This contributed to the annual value of $23.3 million for FY2025, which is 30.40% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Equity Average is $21.1 million, which was down 21.77% from $26.9 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Equity Average peaked at $140.4 million during Q2 2021, and registered a low of $21.1 million during Q3 2025.
  • Over the past 3 years, Aytu Biopharma's median Equity Average value was $31.8 million (recorded in 2024), while the average stood at $32.1 million.
  • As far as peak fluctuations go, Aytu Biopharma's Equity Average spiked by 33.85% in 2021, and later plummeted by 62.80% in 2022.
  • Aytu Biopharma's Equity Average (Quarterly) stood at $108.5 million in 2021, then plummeted by 56.61% to $47.1 million in 2022, then slumped by 30.95% to $32.5 million in 2023, then dropped by 6.81% to $30.3 million in 2024, then declined by 26.77% to $21.1 million in 2025.
  • Its Equity Average was $21.1 million in Q3 2025, compared to $26.9 million in Q2 2025 and $32.8 million in Q1 2025.